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In the title compound, C12H9F3N2O2, the O atoms participate
in hydrogen-bonding interactions with both the NH group and
also the CH groups of adjoining molecules.
Comment
The title compound, (I), is a bicalutamide intermediate.
Bicalutamide is an oral non-steroidal anti-androgen for pros-
tate cancer. It is thought to prevent the growth of prostate
cancer by blocking the effects of androgens on the cancer cells
(Bohl et al., 2005; Tucker et al., 1988). It blocks the effect of
testosterone which is a male sex hormone. Bicalutamide is
often used with another drug that lowers testosterone levels in
the body. Bicalutamide is an antineoplastic hormonal agent,
which is a pure, non-steroidal anti-androgen with affinity for
androgen receptors (but not for progestogen, estrogen, or
glucocorticoid receptors). Consequently, bicalutamide blocks
the action of androgens of adrenal and testicular origin which
stimulate the growth of normal and malignant prostatic tissue.
Prostate cancer is mostly androgen-dependent and can be
treated with surgical or chemical castration. The mechanism of
action of bicalutamide competes with androgen for the
binding of androgen receptors, consequently blocking the
action of androgens of adrenal and testicular origin which
stimulate the growth of normal and malignant prostatic tissue
(Masiello et al., 2002; Schellhammer, 2002; Schellhammer &
Davis, 2004). The crystal structures of related compounds have
been recently reported (Hu & Gu, 2005; Tang & Gu, 2005). In
view of the importance of the title compound and to confirm
the structure, a crystal structure of (I) is reported (Fig. 1).
The C—O distances in the oxirane unit [1.4346 (17) and
1.447 (2) A˚] are within the normal range observed for these
groups (Cambridge Structural Database, Version 5.27; Allen,
2002). The trifluoromethyl group is disordered, as is typically
found for these groups even in structures determined at low
temperatures. The benzene ring and the carboxamide group
are nearly coplanar [dihedral angle = 6.6 (1)]; intramolecular
C6—H6  O1 and N1—H1N  O2 interactions contribute to
their coplanarity. As shown in Fig. 2, there are extensive
intermolecular interactions between the O atoms and the NH
group and also CH groups of adjoining molecules (Table 2).
These link the molecules into hydrogen-bonded dimers by
forming two C—H  O and two N—H  O interactions
involving the oxirane O atom (Fig. 2). These dimers are also
linked to adjoining molecules by weak C—H  O interactions
involving the carbonyl O atom of the carboxamide group.
Experimental
The title compound was obtained as a gift sample from CIPLA,
Mumbai, India. The compound was used without further purification.
Recrystallization from ethanol yielded X-ray diffraction quality
crystals (m.p. 422 K).
Crystal data
C12H9F3N2O2
Mr = 270.21
Monoclinic, P21=n
a = 10.2636 (5) A˚
b = 11.5179 (6) A˚
c = 10.4182 (5) A˚
 = 102.944 (1)
V = 1200.29 (10) A˚3
Z = 4
Dx = 1.495 Mg m
3
Mo K radiation
 = 0.13 mm1
T = 298 (2) K
Block, colorless
0.48  0.37  0.18 mm
Data collection
Bruker APEX-2 CCD area-detector
diffractometer
’ and ! scans
Absorption correction: multi-scan
(SADABS; Sheldrick, 1996)
Tmin = 0.914, Tmax = 0.966
10248 measured reflections
2352 independent reflections
2043 reflections with I > 2(I)
Rint = 0.015
max = 26.0

Refinement
Refinement on F 2
R[F 2 > 2(F 2)] = 0.038
wR(F 2) = 0.107
S = 1.05
2352 reflections
205 parameters
H atoms treated by a mixture of
independent and constrained
refinement
w = 1/[2(Fo
2) + (0.0522P)2
+ 0.266P]
where P = (Fo
2 + 2Fc
2)/3
(/)max < 0.001
max = 0.18 e A˚
3
min = 0.17 e A˚3
Table 1
Selected geometric parameters (A˚, ).
O1—C11 1.2098 (16)
O2—C12 1.4346 (17)
O2—C14 1.447 (2)
N1—C11 1.3595 (18)
N1—C1 1.3972 (16)
C12—C14 1.464 (2)
C4—C41 1.4419 (19)
C41—N41 1.136 (2)
C12—O2—C14 61.07 (10)
O1—C11—N1 124.90 (13)
O1—C11—C12 120.86 (12)
N1—C11—C12 114.20 (11)
O2—C12—C14 59.89 (10)
N41—C41—C4 178.03 (18)
Table 2
Hydrogen-bond geometry (A˚, ).
D—H  A D—H H  A D  A D—H  A
N1—H1N  O2i 0.84 (2) 2.48 (2) 3.243 (2) 151 (1)
C2—H2A  O2i 0.93 2.46 3.264 (2) 145
C14—H14A  O1ii 0.97 2.44 3.375 (2) 161
C6—H6A  O1 0.93 2.30 2.889 (2) 121
N1—H1N  O2 0.84 (2) 2.20 (2) 2.673 (2) 116 (2)
Symmetry codes: (i) x;yþ 2;z; (ii) x 12;yþ 32; z 12.
The trifluoromethyl group was disordered over two conformations
and occupancy factors refined to 0.540 (17) and 0.460 (17). In the
refinement process a common C—F distance was refined to a value of
1.3076 (14) A˚. All H atoms were initially located in a difference
Fourier map. The methyl H atoms were then constrained to an ideal
geometry, with C—H distances of 0.98 A˚ and Uiso(H) = 1.5Ueq(C),
but each group was allowed to rotate freely about its C—C bond. All
other carbon-bound H atoms were placed in geometrically idealized
positions and constrained to ride on their parent atoms, with C—H
distances in the range 0.95–1.00 A˚ and Uiso(H) = 1.2Ueq(C). The
positional parameters for the amine H atom were refined with
Uiso(H) = 1.2Ueq(N).
Data collection: APEX2 (Bruker, 2006); cell refinement: SAINT
(Bruker, 2004); data reduction: SAINT; program(s) used to solve
structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine
structure: SHELXL97 (Sheldrick, 1997); molecular graphics:
SHELXTL (Bruker, 2003); software used to prepare material for
publication: SHELXTL.
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Figure 1
The molecular structure of (I), showing the atom-numbering scheme.
Displacement ellipsoids are drawn at the 20% probability level. Only the
major conformer of the disordered trifluoromethyl group is shown.
Figure 2
The molecular packing for (I), viewed down the a axis. Only the major
conformer of the disordered trifluoromethyl group is shown. Hydrogen
bonds are indicated by dashed lines.
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